CN116098894A - Application of Mitochonic acid 5 in treating tumor - Google Patents

Abstract

The invention discloses an application of Mitochonic acid 5 in treating tumors, and the invention discovers that Mitochonic acid 5 has a treatment effect on tumors for the first time, and experiments prove that Mitochonic acid 5 has an obvious inhibition effect on the migration speed of tumor cells. The novel application of Mitochord acid 5 discovered by the invention provides a novel thought for treating tumors and has wide application prospect.

Description

Application of Mitochonic acid 5 in treating tumor

Technical Field

The invention belongs to the field of biological medicine, and in particular relates to an application of Mitochonic acid 5 in treating tumors.

Background

Since 2010, the incidence and mortality of cancer in China have been increasing. At present, the cancer mortality rate exceeds that of cardiovascular and cerebrovascular diseases, and the cancer has become a 'first killer' for various diseases. It is estimated that about 2,814,000 patients die in 2015 in China, with an average of 7500 cancer patients die each day. In China, lung cancer, bronchus cancer, gastric cancer, liver cancer and esophagus cancer account for 3/4 of the death rate of cancer. The incidence and death rate of cancer in China are all at a higher level in the world, and the situation of rising year by year is presented, so that the task of preventing and treating the cancer is extremely difficult. In addition, metastasis is a major cause of cancer death. The transfer includes several sequential steps including invasion, introgression, circulation and extravasation. However, due to its complexity, metastasis is the least well known process in tumor progression. There is also currently no drug effective in inhibiting metastasis for restricted migration.

Drug therapy has been a popular research and development in the field of tumor therapy, drug repositioning (Drug resumption) is also called Drug Rediscovery or old Drug new use, and is a new Drug research and development mode with the lowest research and development cost and the shortest research and development period, wherein the Drug therapy is to redetermine the therapeutic indication for drugs which are already on the market or fail to be on the market, so that a plurality of links of compound screening and preclinical verification can be omitted.

At present, the application range of Mitochonic acid 5 is for improving the injury of renal tubules and myocardial cells, and the relevance between Mitochonic acid 5 and tumors has not been reported yet, so that the application of Mitochonic acid 5 in tumor treatment is studied, and the Mitochonic acid 5 has important significance for tumor treatment.

Disclosure of Invention

In order to make up the defects of the prior art, the invention discovers that the Mitochonic acid 5 can inhibit the migration of tumors and has obvious treatment effect on the tumors by researching the relativity between the Mitochonic acid 5 and the tumors.

In order to achieve the above purpose, the invention adopts the following technical scheme:

the first aspect of the invention provides the use of Mitochonic acid 5 in the manufacture of a pharmaceutical composition for the treatment of tumours.

Further, the mitochoronic acid 5 inhibits metastasis of tumors.

Further, the mitochoronic acid 5 inhibits tumor metastasis by inhibiting ATP production and/or mitochondrial distribution.

Further, the concentration of Mitochonic acid 5 is 0-40. Mu.M.

Further, the concentration of mitochoronic acid 5 is selected from the group consisting of: 2.5. Mu.M, 10. Mu.M, 40. Mu.M, and ranges between any two of the above.

Further, the pharmaceutical composition also comprises pharmaceutically acceptable carriers and/or auxiliary materials.

Further, the pharmaceutically acceptable carrier and/or adjuvant comprises diluent, binder, surfactant, wetting agent, adsorption carrier, lubricant, filler, and disintegrating agent.

Further, the pharmaceutical composition also comprises other medicaments for treating tumors.

Further, the other drugs for treating tumors comprise chemotherapeutic drugs, targeting drugs, hormonal drugs, antibody drugs, immunotherapeutic drugs, biological response modifiers and/or traditional Chinese medicine preparations.

Further, the tumor is a cancer.

Further, the cancer is selected from liver cancer, lung cancer, pancreatic cancer, and breast cancer.

In a second aspect, the invention provides a pharmaceutical composition for treating a tumor, the pharmaceutical composition comprising a therapeutically effective amount of mitochoronic acid 5.

Further, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

Further, the pharmaceutical composition also comprises other medicaments for treating tumors.

Further, the other drugs for treating tumors comprise chemotherapeutic drugs, targeting drugs, hormonal drugs, antibody drugs, immunotherapeutic drugs, biological response modifiers and/or traditional Chinese medicine preparations.

Further, the tumor is a cancer.

Further, the cancer is selected from liver cancer, lung cancer, pancreatic cancer, and breast cancer.

In a third aspect the invention provides a method of inhibiting metastasis of a tumor cell in vitro, the method comprising administering mitochonic acid 5.

Further, the mitochoronic acid 5 inhibits metastasis of tumor cells by inhibiting ATP production and/or mitochondrial distribution.

Further, the method is a method for non-therapeutic purposes.

Further, the tumor is a cancer.

Further, the cancer is selected from liver cancer, lung cancer, pancreatic cancer, and breast cancer.

In a fourth aspect, the invention provides the use of mitochoronic acid 5 in inhibiting tumor cell metastasis in vitro.

Further, the mitochoronic acid 5 inhibits metastasis of tumor cells by inhibiting ATP production and/or mitochondrial distribution.

Further, the tumor is a cancer.

Further, the cancer is selected from liver cancer, lung cancer, pancreatic cancer, and breast cancer.

The invention has the advantages and beneficial effects that:

the invention discovers the relativity between Mitochonic acid 5 and tumor for the first time, and Mitochonic acid 5 can inhibit the migration of tumor by inhibiting the generation of ATP and/or the distribution of mitochondria, thereby achieving the effect of treating tumor. The Mitochord acid 5 provided by the invention has low application and research cost and short research and development period in tumor treatment, and has wide application prospect in clinic.

Drawings

FIG. 1 is a drug screening diagram, wherein 1A is a screening drug diagram and 1B is a Wen diagram;

FIG. 2 is a graph showing cell migration, wherein 2A is a graph showing liver cancer cell activity, 2B is a graph showing lung cancer cell activity, 2C is a graph showing liver cancer cell scratch experiment, 2D is a graph showing lung cancer cell scratch experiment, 2E is a graph showing liver cancer cell migration velocity statistics, and 2F is a graph showing lung cancer cell migration velocity statistics;

FIG. 3 is a graph showing ATP production and mitochondrial distribution, wherein 3A is an ATP level map and 3B is a confocal microscopy image.

Detailed Description

The following provides definitions of some of the terms used in this specification. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

The term "treatment" refers to the medical management of a patient with the aim of curing, ameliorating, stabilizing or preventing a disease, pathological state or condition. The term includes active therapies, i.e., therapies directed specifically to ameliorating a disease, pathological condition or disorder, and also includes causal therapies, i.e., therapies directed to removing the etiology of the associated disease, pathological condition or disorder. Furthermore, the term also includes palliative treatment, i.e. treatment designed to alleviate symptoms rather than cure a disease, pathological state or condition; the term also includes prophylactic treatment, i.e., treatment with the aim of minimizing or partially or completely inhibiting the development of a related disease, pathological state or disorder; and supportive treatment, i.e., treatment for supplementing another specific therapy aimed at ameliorating the associated disease, pathological state, or condition. In particular, the term "treatment" refers to the inhibition, alleviation, amelioration, slowing, stopping, delaying or reversing of the progression or exacerbation of a disease, in order to prevent or reduce the occurrence or progression of the disease, and the various indicators of the disease, disorder or pathological state described as maintaining and/or administering include alleviation or reducing symptoms or complications, or curing or eliminating the disease, disorder or condition.

The term "inhibit" or "reduce" refers to the ability to cause a 20%,30%,40%,50%,60%,70%,75%,80%,85%,90%,95%, or greater overall reduction. Inhibition or reduction may refer to the production of a substance, in the present invention, inhibition of ATP production. In addition, inhibition or reduction may refer to, for example, symptoms of the condition being treated, the presence or size of metastases, or the size of the primary tumor. In the present invention, inhibition or reduction refers to inhibition of metastasis of a tumor.

The term "tumor" refers to a neoplasm formed by the alteration of normal tissue cells in a human, and the formation of hyperproliferative tumors, including benign tumors as well as malignant tumors. Benign tumors such as hepatic hemangioma, renal hamartoma, uterine fibroids. Benign tumors often grow slowly, do not metastasize far away, and rarely recur after surgical resection. Cancer is a collective term for all malignant tumors.

In the present invention, cancer refers to the malignant growth of cells in skin or body organs including, but not limited to, breast, prostate, lung, kidney, pancreas, stomach, or intestine. In the present invention, cancers include, but are not limited to, adrenocortical carcinoma, adult primary unknown carcinoma, adult malignant mesothelioma, aids-related cancers, anal carcinoma, appendicular carcinoma, astrocytoma (cerebellar astrocytoma, cerebral astrocytoma, childhood cerebral astrocytoma), basal cell carcinoma, cholangiocarcinoma, bladder carcinoma, bone tumor, brain cancer, breast cancer, bronchial adenoma/carcinoid, carcinoid tumor, primary unknown carcinoma, cervical cancer, chronic myeloproliferative disorders, colon cancer, connective tissue-promoting small round cell tumor, endometrial carcinoma, ependymoma, epithelial-like vascular endothelial tumor (EHE), esophageal carcinoma, ewing's tumor sarcoma family, extracranial germ cell tumor, extragonadal germ cell tumor, ocular cancer, gallbladder cancer gastrointestinal stromal tumor (GIST), gestational trophoblastoma, glioma, colorectal cancer, head and neck cancer, heart cancer, liver cancer, islet cell carcinoma (endocrine pancreas), kaposi's sarcoma, renal cancer (renal cell carcinoma), laryngeal carcinoma, leukemia (acute lymphoblastic leukemia, chronic lymphocytic leukemia (also known as chronic lymphocytic leukemia), chronic myelogenous leukemia (also known as chronic myelogenous leukemia), hairy cell leukemia), lip cancer, liposarcoma, lung cancer (non-small cell lung cancer, small cell lung cancer), lymphoma (non-hodgkin's lymphoma, aids-related lymphoma, burkitt's lymphoma, central nervous system lymphoma, skin T cell lymphoma), megaloblastic, bone malignant fibrous histiocytoma/osteosarcoma, medulloblastoma, melanoma, merkel cell carcinoma, primary focal occult metastatic cervical squamous carcinoma, multiple endocrine tumor syndrome, myelocarcinoma, multiple myeloma/plasma cell neoplasm, mycotic mycosis, myelodysplastic syndrome, myxoma, nasal and paranasal sinus cancer, neuroblastoma, ovarian cancer, ovarian epithelial cancer (surface epithelial mesenchymal tumor), ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, parathyroid cancer, penile cancer, pharyngeal cancer (hypopharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer,), pheochromocytoma, and pineal germ cell tumor, pineal blastoma, supracurtain primitive neuroectodermal tumor, pituitary adenoma, pleural pneumoblastoma, prostate cancer, rectal cancer, renal pelvis and ureteral transitional cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland carcinoma, szary syndrome, merkel cell skin carcinoma, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, testicular cancer, thymoma, thyroid cancer, urinary tract cancer, uterine sarcoma, vaginal carcinoma, vulval carcinoma, waldenstrom macroglobulinemia, and wilms' tumor.

In an embodiment of the invention, the cancer is selected from liver cancer, lung cancer, pancreatic cancer, breast cancer.

The pharmaceutical composition of the present invention may be in a dosage form advantageous for administration prepared by a conventional method, including but not limited to aqueous injection, powder injection, pill, powder, tablet, patch, suppository, emulsion, cream, gel, granule, capsule, aerosol, spray, powder spray, sustained release agent and controlled release agent.

The pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, bucally, vaginally, or by an implanted reservoir. Oral administration or injection administration is preferred. The pharmaceutical compositions of the present invention may contain any of the usual non-toxic pharmaceutically acceptable carriers, adjuvants or excipients. In some cases, a pharmaceutically acceptable acid, base or buffer may be used to adjust the pH of the formulation to improve the stability of the formulated compound or dosage form thereof. Parenteral administration as described herein includes subcutaneous, intradermal, intravenous, intramuscular, intra-articular, intra-arterial, intra-synovial, intrasternal, intra-jugular, intralesional, and intracranial injection or infusion techniques. The pharmaceutical composition of the present invention may be administered to the subject by any route so long as the target tissue is achieved.

For oral administration, the pharmaceutical composition forms include, but are not limited to, tablets, capsules, liquid capsules, suspensions or liquids.

In the present invention, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, which may contain inert ingredients that do not unduly inhibit the biological activity of the compound. The pharmaceutically acceptable carrier should be biocompatible, e.g., non-toxic, non-inflammatory, non-immunogenic, or free of other undesirable reactions or side effects upon administration to a subject. Standard pharmaceutical formulation techniques may be used.

Pharmaceutically acceptable carriers and/or excipients are described in detail in Remington's Pharmaceutical Sciences (19 th ed., 1995) and include, but are not limited to, diluents, binders, surfactants, wetting agents, adsorption carriers, lubricants, fillers, disintegrants. These substances are used as needed to aid stability of the formulation or to aid in enhancing the activity or its bioavailability or to give acceptable mouthfeel or odor in the case of oral administration, and the formulation which may be used in such a pharmaceutical composition may be in the form of its original compound itself or optionally in the form of its pharmaceutically acceptable salt, and the pharmaceutical composition so formulated may be administered by any suitable means known to those skilled in the art as needed.

Wherein the diluents include, but are not limited to lactose, sodium chloride, dextrose, urea, starch, water.

Binders include, but are not limited to, starch, pregelatinized starch, dextrin, maltodextrin, sucrose, acacia, gelatin, methylcellulose, carboxymethylcellulose, ethylcellulose, polyvinyl alcohol, polyethylene glycol, polyvinyl pyrrolidone, alginic acid and its salts, xanthan gum, hydroxypropyl cellulose and hydroxypropyl methylcellulose.

Surfactants include, but are not limited to, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, monoglyceride of stearic acid, cetyl alcohol.

The wetting agent includes, but is not limited to, glycerin, starch.

Adsorption carriers include, but are not limited to, starch, lactose, bentonite, silica gel, kaolin, and soap clay.

Lubricants include, but are not limited to, zinc stearate, glycerol monostearate, polyethylene glycol, talc, calcium and magnesium stearate, polyethylene glycol, boric acid powder, hydrogenated vegetable oil, sodium stearyl fumarate, polyoxyethylene monostearate, monolauryl saccharate, sodium lauryl sulfate, magnesium lauryl sulfate, and magnesium lauryl sulfate.

Fillers include, but are not limited to, mannitol (granular or powdered), xylitol, sorbitol, maltose, erythrose, microcrystalline cellulose, polymeric sugars, coupling sugars, glucose, lactose, sucrose, dextrin, starch, sodium alginate, laminarin powder, agar powder, calcium carbonate, and sodium bicarbonate.

Disintegrants include, but are not limited to, crospovidone, sodium carboxymethyl starch, low substituted hydroxypropyl methyl, croscarmellose sodium, and soy polysaccharide.

In the invention, the pharmaceutical composition also comprises other medicines for treating tumors, and the medicines for treating tumors are not limited to the chemotherapeutic medicines, the targeting medicines, the hormone medicines, the antibody medicines, the immune therapeutic medicines, the biological response modifier and/or the traditional Chinese medicine preparation, so long as the effects of treating tumors are all within the protection scope of the invention.

The term "chemotherapeutic agent" is a drug that treats a tumor. Chemotherapeutic agents kill tumor cells. The medicines can act on different links of the growth and propagation of tumor cells to inhibit or kill the tumor cells.

In the present invention, chemotherapeutic agents include, but are not limited to, cytotoxic agents, DNA damaging agents, anthracyclines, vinblastine agents, taxoids, platinum agents, fluorouracil agents.

Among them, cytotoxic drugs, DNA damaging drugs, including but not limited to alkylating agents, ifosfamide, cyclophosphamide. Anthracyclines including, but not limited to, epirubicin, pirarubicin, doxorubicin, epirubicin. Vinblastine drugs, including but not limited to vincristine, vindesine, and vinblastine. Paclitaxel drugs including, but not limited to, docetaxel, paclitaxel, albumin paclitaxel, and paclitaxel liposomes. Platinum-based drugs including, but not limited to, cisplatin, carboplatin, nedaplatin, lobaplatin, oxaliplatin. Fluorouracil drugs, including but not limited to capecitabine, tegafur.

The term "targeted drug" refers to a drug or formulation thereof that is endowed with targeting ability. The purpose is to target the drug or its carrier to a specific lesion and accumulate or release the active ingredient at the target site.

In the present invention, the targeting drug includes, but is not limited to, a liver cancer targeting drug, a lung cancer targeting drug, a pancreatic cancer targeting drug, and a breast cancer targeting drug.

Among them, liver cancer targeting drugs include, but are not limited to: epidermal growth factor receptor inhibiting agents including, but not limited to An Luoti, lapatinib, gefitinib, and cetuximab. Vascular endothelial growth factor receptor antagonists including, but not limited to, varanib, bevacizumab, recombinant human vascular endothelial inhibin (endegree). Inhibitors of multiple kinases including, but not limited to, sorafenib, sunitinib, and some mammalian target inhibitors of rapamycin.

Lung cancer targeting drugs include, but are not limited to: small molecule tyrosinase inhibitors (EGFR-TKI) directed against epidermal growth factor receptors, including, but not limited to erlotinib (tarceva), gefitinib (iressa) and icotinib (kemelna), afatinib, dacatinib, oxatinib. Small molecule tyrosinase inhibitors (ALK-TKIs) directed against anaplastic lymphoma kinase fusion genes including, but not limited to, crizotinib, ceritinib, aletinib. Targeted drugs against vascular endothelial growth factor include, but are not limited to bevacizumab (avastin) and recombinant human vascular endothelial inhibin injection (endegree). Monoclonal antibodies directed against epidermal growth factor, mainly cetuximab (erbitux).

Pancreatic cancer targeting drugs include, but are not limited to: an inhibitor for inhibiting the tyrosine kinase, i.e. lotinib; everolimus with MTor as a target and rtk as a small molecule multi-target receptor tyrosine kinase inhibitor, including sunitinib.

Breast cancer targeted drugs include, but are not limited to, her2 targeted herceptin, lapatinib, mixed formulations, bevacizumab, enness, lapatinib and apatinib for vegf, everolimus for mTOR inhibitors, inhibitors for 0D4, CD6, inhibitors for ESR.

In the present invention, hormonal agents include, but are not limited to, letrozole, anastrozole, aminoglutethimide, tamoxifen, and flutamide.

Antibodies include, but are not limited to, bevacizumab, trastuzumab, cetuximab.

Immunotherapeutic agents include, but are not limited to, pamizumab, nivolumab.

Biological response modifiers include, but are not limited to, interleukins and interferons.

The term "effective amount" refers to an amount of a drug that is effective to treat a disease or disorder in a mammal, alone or in combination with other drugs or treatment regimens. In the case of cancer, a therapeutically effective amount of the drug may reduce the number of cancer cells; reducing the size of the tumor; inhibit (i.e., slow and preferably prevent to some extent) infiltration of cancer cells into surrounding organs; inhibit (i.e., slow and preferably prevent to some extent) tumor metastasis; inhibit tumor growth to a certain extent; and/or to some extent, alleviate one or more symptoms associated with the disorder. To the extent that the drug can prevent the growth of and/or kill existing cancer cells, it can be cytostatic and/or cytotoxic. For cancer therapy, in vivo efficacy may be measured, for example, by assessing survival duration, progression Free Survival (PFS) duration, response Rate (RR), response duration, and/or quality of life.

The term "administering" refers to a method of administering a dose of a drug or compound or pharmaceutical composition to a subject (e.g., patient). Administration may be by any suitable means, including parenteral, intrapulmonary and intranasal, and if desired for topical treatment, intralesional administration. Parenteral infusion includes, for example, intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administration. Depending in part on whether the administration is brief or chronic, the administration may be by any suitable route, for example by injection, such as intravenous or subcutaneous injection. Various dosing schedules are contemplated in the present invention, including, but not limited to, single administration or multiple administrations over multiple time points, bolus administration and pulse infusion.

The subject refers to any animal, and also refers to human and non-human animals. Non-human animals include all vertebrates, for example, mammals, such as non-human primates (particularly higher primates), sheep, dogs, rodents (such as mice or rats), guinea pigs, goats, pigs, cats, rabbits, cattle, and any domestic animals or pets; and non-mammals such as chickens, amphibians, reptiles, and the like. In a preferred embodiment of the invention, the subject is preferably a human.

The invention is further illustrated below in connection with specific embodiments. It should be understood that the particular embodiments described herein are presented by way of example and not limitation. The principal features of the invention may be used in various embodiments without departing from the scope of the invention.

Example Mitchronic acid 5 reduces migration velocity of tumor cells

1. Experimental materials

Liver cancer cell line: SK-Hep-1, SNU499, non-small cell lung cancer cell line: h1299, a549, pancreatic cancer cell line: SW1990, breast cancer cells: MDA-MB-231.

Cell lines were purchased from ATCC in DMEM medium, 5% CO ₂ Culturing at 37 ℃.

2. Experimental method

Drug screening

The method comprises the steps of screening drugs for inhibiting tumor cell migration by using a microfluidic-based limiting migration drug screening platform, wherein tumor cells are selected from liver cancer cells (SK-Hep-1), pancreatic cancer cells (SW 1990), non-small cell lung cancer cells (A549) and breast cancer cells (MDA-MB-231), adding the cells into one channel of the limiting migration drug screening platform, adding related drugs into the other channel for screening, and screening layer by layer through each channel to obtain target drugs.

MTT method for detecting influence of screening drugs on cell activity

Liver cancer cells (SK-Hep-1, SNU 499), non-small cell lung cancer cells (H1299, A549) were seeded onto 96-well plates, 2000 cells per well, and each sample was repeated 3 times. After 24 hours incubation of the drug, cell viability was checked with thiazole blue (MTT) (MedChemExpress, usa) and used every 24 hours for the next 5 days. Absorbance was measured for each well using a 560nm microplate reader (BioTek, agilent, USA).

Ibidi chamber scratch experiment for detecting influence of screening drugs on tumor cell migration

In Ibidi culture dish

Munich, germany) was subjected to a scratch-free wound healing experiment, the dish consisting of two cell culture chambers 500 μm wide. Each chamber was inoculated with 70. Mu.L of the cell suspension at a concentration of 5X 10 ⁵ Cells/ml. After 8 hours, the cells were completely adhered to the bottom of the cavity and the inserts were removed. Then, drugs and media of different concentrations were added to the wells, and the wound healing rate was observed by standing for 24 hours, and mitochondrial distribution was observed using a confocal microscope (Nikon, A1HD25, japan).

Screening drugs for effects on ATP detection production

ATP concentrations were measured using an enhanced ATP assay kit (Beyotime, china) according to manufacturer's protocol. Cells were lysed with ATP lysis buffer (200. Mu.L of lysis solution per well, 6 well plate), centrifuged at 15,000g for 5min at 4 ℃. The supernatant was collected and stored in ice. Before the ATP assay, 100. Mu.L of ATP working solution (ATP assay solution: ATP assay solution diluted 1:5) was added to a 1.5mL EP tube and incubated at room temperature for 3-5min. The supernatant was transferred to 100. Mu.L of ATP working solution and stirred well. The amount of luminescence was measured immediately with a luminescence functional microplate reader (BioTek, agilent, USA). And normalizing the luminescence data and the protein amount of the sample.

Confocal microscopy observations of the effects of drug screening on mitochondrial distribution

Cells transfected with pCMV-Mito-AT1.03 plasmid were plated on confocal dishes and raw images (mitochondria and DAPI) were acquired using a confocal microscope (Nikon, A1HD25, japan). Binary images and mitochondrial morphology skeletons were transformed from the original images and measured using mitochondrial network analysis (MiNA, https:// gitub. Com/StuartLab/MiNA) in Fiji image J of image J.

3. Experimental results

And (3) screening out the medicine Mitchronic acid 5 (figure 1) with an effect on four cell lines of liver cancer, pancreatic cancer, non-small cell lung cancer and breast cancer by using a limited migration medicine screening platform.

MTT detection results show that Mitchronic acid 5 has no effect on liver cancer and non-small cell lung cancer cell activity (FIGS. 2A and 2B); the scratch test results showed that mitchelonic acid 5 inhibited the rate of cell migration in the scratch test (fig. 2C-2F); mitchronic acid 5 inhibited ATP production and mitochondrial distribution, thereby reducing cell migration rate (FIG. 3).

The above description of the embodiments is only for the understanding of the method of the present invention and its core ideas. It should be noted that it will be apparent to those skilled in the art that several improvements and modifications can be made to the present invention without departing from the principle of the invention, and these improvements and modifications will fall within the scope of the claims of the invention.

Claims (10)

1. Use of 1.Mitochornic acid 5 in the preparation of a pharmaceutical composition for the treatment of a tumour.
2. 2. The use according to claim 1, wherein the mitochonic acid 5 inhibits metastasis of a tumor.
3. 3. The use according to claim 2, wherein the mitochonic acid 5 inhibits metastasis of tumors by inhibiting ATP production and/or mitochondrial distribution.
4. 4. The use according to claim 1, wherein the concentration of mitochonic acid 5 is 0-40 μm;

   preferably, the concentration of mitochoronic acid 5 is selected from: 2.5. Mu.M, 10. Mu.M, 40. Mu.M, and ranges between any two of the above.
5. 5. The use according to claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and/or adjuvant;

   preferably, the pharmaceutically acceptable carrier and/or adjuvant comprises diluent, binder, surfactant, wetting agent, adsorption carrier, lubricant, filler, and disintegrating agent.
6. 6. The use according to claim 1, wherein the pharmaceutical composition further comprises other medicaments for the treatment of tumors;

   preferably, the other medicines for treating tumors comprise chemotherapeutic medicines, targeting medicines, hormone medicines, antibody medicines, immunotherapeutic medicines, biological response modifiers and/or traditional Chinese medicine preparations;

   preferably, the tumor is a cancer;

   preferably, the cancer is selected from liver cancer, lung cancer, pancreatic cancer, breast cancer.
7. 7. A pharmaceutical composition for treating a tumor, the pharmaceutical composition comprising a therapeutically effective amount of mitochoronic acid 5;

   preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
8. 8. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition further comprises other drugs for treating tumors;

   preferably, the other medicines for treating tumors comprise chemotherapeutic medicines, targeting medicines, hormone medicines, antibody medicines, immunotherapeutic medicines, biological response modifiers and/or traditional Chinese medicine preparations;

   preferably, the tumor is a cancer;

   preferably, the cancer is selected from liver cancer, lung cancer, pancreatic cancer, breast cancer.
9. 9. A method of inhibiting metastasis of a tumor cell, comprising administering mitochoronic acid 5;

   preferably, the mitochoronic acid 5 inhibits metastasis of tumor cells by inhibiting ATP production and/or mitochondrial distribution;

   preferably, the tumor is a cancer;

   preferably, the cancer is selected from liver cancer, lung cancer, pancreatic cancer, breast cancer.
10. Use of 10.Mitochornic acid 5 for inhibiting tumor cell metastasis;

    preferably, the mitochoronic acid 5 inhibits metastasis of tumor cells by inhibiting ATP production and/or mitochondrial distribution;

    preferably, the tumor is a cancer;

    preferably, the cancer is selected from liver cancer, lung cancer, pancreatic cancer, breast cancer.

Images